ACADIA (ACAD) Q1 FY26 earnings call

ACADIA Pharmaceuticals delivered a solid Q1 FY26, driven by robust DAYBUE sales and the successful launch of DAYBUE STIX, while NUPLAZID demonstrated strong underlying demand despite temporary refill delays that have since normalized. The company reaffirmed its full-year guidance and highlighted significant pipeline catalysts, including the upcoming Phase II readout for remlifanserin in Alzheimer's disease psychosis and accelerated results for trofinetide in Japan, positioning ACADIA for continued growth.